Adamis Pharmaceuticals Corporation Net Income 2011-2026 | ADMP

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Adamis Pharmaceuticals Corporation

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-26.5 M	-45.8 M	-49.4 M	-29.3 M	-39 M	-25.5 M	-19.4 M	-13.6 M	-8.16 M	-7.19 M	-4.92 M	-6.98 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-4.92 M	-49.4 M	-23 M

Quarterly Net Income Adamis Pharmaceuticals Corporation

2023-Q3	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-1.39 M	-8.94 M	-	-4.4 M	-8.4 M	-10.4 M	-	-12.4 M	-9.31 M	-15.4 M	-	-11.4 M	-12.9 M	-7.25 M	-	-7 M	-7.74 M	-8.89 M	-	-8.88 M	-9.7 M	-7.62 M	-	-6.77 M	-4.97 M	-5.77 M	-	-6.64 M	-5.71 M	-6.41 M	-	-3.15 M	-3.64 M	-3.14 M	-	-2.12 M	-2.88 M	-1.55 M	-5.53 M	-32 K	-1.07 M	-	-1.97 M	-5.56 M	-3.58 M	-	-991 K	-3.71 M	-2.72 M	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-32 K	-15.4 M	-6.05 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Drug manufacturers industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
AcelRx Pharmaceuticals ACRX	-14.3 M	-	7.5 %	$ 6.35 M	USA
Agile Therapeutics AGRX	-14.5 M	-	10.11 %	$ 58.2 M	USA
Aerie Pharmaceuticals AERI	-74.8 M	-	-	$ 754 M	USA
Catalent CTLT	-1.04 B	-	-	$ 11.5 B	USA
Eagle Pharmaceuticals EGRX	35.6 M	-	-39.89 %	$ 27.7 M	USA
Endo International plc ENDP	-2.45 B	-	-	$ 28.9 M	Irlanda
DURECT Corporation DRRX	-27.6 M	-	-	$ 50.1 M	USA
Alimera Sciences ALIM	-20.1 M	-	-	$ 142 M	USA
Athenex ATNX	-103 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	-48.8 M	-	-	$ 2.06 B	France
Evoke Pharma EVOK	-7.79 M	-	-	$ 36.6 M	USA
Cumberland Pharmaceuticals CPIX	-1.9 M	$ 3.12	-	$ 43.9 M	USA
Cronos Group CRON	-73.1 M	$ 2.61	1.36 %	$ 1.34 B	Canada
Calliditas Therapeutics AB (publ) CALT	-510 M	-	-0.1 %	$ 2.03 B	Schweden
HEXO Corp. HEXO	-115 M	-	2.45 %	$ 38.1 M	Canada
Bausch Health Companies BHC	-592 M	$ 5.8	1.4 %	$ 2.12 B	Canada
Harrow Health HROW	-5.14 M	$ 38.15	2.83 %	$ 1.4 B	USA
Aurora Cannabis ACB	-695 M	$ 3.57	2.44 %	$ 86.3 M	Canada
Canopy Growth Corporation CGC	-598 M	$ 1.11	2.31 %	$ 119 M	Canada
Jupiter Wellness JUPW	-68.2 M	-	-	$ 33.6 M	USA
Lannett Company LCI	-232 M	-	1.15 %	$ 7.11 M	USA
OrganiGram Holdings OGI	-131 M	$ 1.47	3.17 %	$ 402 M	Canada
Neoleukin Therapeutics NLTX	-90.4 M	-	-	$ 193 M	Canada
Evolus EOLS	-51.6 M	$ 4.36	0.7 %	$ 281 M	USA
Emergent BioSolutions EBS	-760 M	$ 8.34	1.21 %	$ 427 M	USA
Sundial Growers SNDL	-230 M	$ 1.39	1.42 %	$ 3.37 M	Canada
Tilray TLRY	-1.45 B	$ 7.0	4.17 %	$ 4.33 B	Canada
Organogenesis Holdings ORGO	861 K	$ 2.39	0.42 %	$ 315 M	USA
Pacira BioSciences PCRX	-99.6 M	$ 24.32	1.06 %	$ 1.12 B	USA
PetIQ PETQ	2.13 M	-	1.64 %	$ 400 M	USA
Veru VERU	-37.8 M	$ 2.4	1.05 %	$ 324 M	USA
ProPhase Labs PRPH	18.5 M	-	-	$ 5.07 M	USA
Viatris VTRS	54.7 M	$ 13.84	0.07 %	$ 16.6 B	USA
Relmada Therapeutics RLMD	-57.4 M	$ 7.42	0.54 %	$ 293 M	USA
cbdMD YCBD	-153 K	$ 0.75	1.28 %	$ 3.23 M	USA
Assertio Holdings ASRT	-30.4 M	$ 18.1	0.44 %	$ 116 M	USA
Radius Health RDUS	-70.2 M	-	-	$ 1.42 B	USA
Recro Pharma REPH	-13.3 M	-	-4.76 %	$ 65.3 M	USA
OptiNose OPTN	-35.5 M	-	-	$ 1.08 B	USA
SCYNEXIS SCYX	-8.61 M	$ 1.03	1.98 %	$ 51.4 M	USA
PLx Pharma PLXP	-46.1 M	-	-27.8 %	$ 2.56 M	USA
Solid Biosciences SLDB	-174 M	$ 8.59	2.38 %	$ 752 M	USA
Sonoma Pharmaceuticals SNOA	-3.46 M	$ 2.35	-	$ 2.92 M	USA
Zomedica Corp. ZOM	-81.9 M	-	-0.21 %	$ 98 M	USA
Zynerba Pharmaceuticals ZYNE	-35 M	-	-	$ 55.5 M	USA
Rockwell Medical RMTI	-5.31 M	$ 0.91	-2.69 %	$ 32.7 M	USA
Tricida TCDA	-177 M	-	-	$ 3.25 M	USA
China Pharma Holdings CPHI	-3.19 M	$ 0.65	-	$ 2.79 M	China
TherapeuticsMD TXMD	-569 K	$ 2.03	-0.98 %	$ 23.5 M	USA